The biopharmaceutical company Biopharma begins to conduct EIA (enzyme immunoassay) tests for availability of COVID-19 antibody assay for all plasma donors, EIA testing will identify those who have the disease in a latent form.
“Biopharma purchased 12,000 EIA tests manufactured by Roche and on May 18 we will begin testing donors for antibodies on our hardware base,” Kostiantyn Yefymenko, the co-owner of the company, said on his Facebook page.
He recalled that Biopharma has begun collecting plasma from donors who have undergone COVID-19.
“The first liters of such plasma have already been prepared, and our team is doing a very difficult job. We understood that it would not be easy. Very difficult,” he wrote.
Yefymenko noted that the number of potential donors is very limited. So, out of 4,700 people who recovered (at the time of publishing the post of Yefymenko) in Ukraine, 40% are older than 60 years and cannot be donors, 20% cannot be donors according to their indications.
“There remain 1,800 people in a large, forty-million country, who need to be found, and not all, but volunteers who are ready to become a donor,” he explained.
As reported, Biopharma has begun the development of a hyperimmune immunoglobulin based on plasma of people who had COVID-19, this drug can be effective for specific treatment of COVID-19.
Biopharma is a Ukrainian biotechnology company, the only plant in Eastern Europe that has modern technology, has been manufacturing and developing drugs from donated plasma for almost 50 years.
The European Aviation Safety Agency (EASA) has included all airports in the Kyiv and Chernivtsi regions in the list of airports located in the affected areas with a high risk of transmission of COVID-19 infection.
According to a message published on the EASA website on May 12, the list of risky airports was developed in coordination with EASA member states and is based on information from the World Health Organization, the European Center for Disease Prevention and Control and other reputable public health institutes.
The updated list takes effect on May 14. In total, airports from 32 countries of the world, including in the United States, Russia and Great Britain, were included in the risk list.
Double liability company Interchem, a pharmaceutical company based in Odesa, has received the permit of the Health Ministry of Ukraine for conducting clinical testing of antiviral medicine Amixin for effectiveness in treatment of coronavirus (COVID-19).
Director General of the company Anatoliy Reder told Interfax-Ukraine that a respective decree of the Health Ministry was signed on May 14.
He also said that the company requested the consideration of the application on clinical trials of Amixin due to the fact that the medicine had previously shown its effectiveness against a number of dangerous viral infections. During preclinical trials, it was proved that tilorone (the active substance of Amixin medicine) has antiviral activity against a number of strains of ordinary coronaviruses.
Several international research centers have already conducted and are carrying out testing of tilorone against SARS-CoV-2 coronavirus.
“As we can see, not only do we consider Amixin as a potentially effective medicine against COVID-19, but also researchers abroad,” he said.
Reder said that, in particular, such trials were conducted at the Institut Pasteur Korea (South Korea), and in two research centers in the United States as well.
“Based on the data of preclinical trials showing the highly effective antiviral effect of tilorone against SARS-CoV-2, we applied to the Health Ministry for approval of the third phase of clinical testing to expand the range of use of Amixin medicine and obtain evidence on its efficiency and safety for treating patients with COVID-19 infection,” he said.
According to Reder, clinical trials of Amixin will be conducted by research centers in three cities of Ukraine. In general, a trial may take three to four months from the moment the Health Ministry gave a permit for conducting it to the pharmaceutical company.
“The duration of the clinical trial will primarily depend on the speed of patient enrollment. At this stage, it is planned to include more than 60 volunteers in the study who, according to the severity of the disease, will be on self-isolation and undergo outpatient treatment,” he said.
Reder said that the research doctors who confirmed their readiness to conduct this trial are highly motivated, first of all, by their scientific interest and the opportunity to make their contribution to the search for a solution, which is so urgent for the whole world of medical and social problem that the new coronavirus has become.
Interchem is one of the leading pharmaceutical companies in the country.
Pharmaceutical manufacturers of Ukraine register clinical trials of medicines for the treatment of coronavirus (COVID-19), Health Minister Maksym Stepanov has said.
“There are internal enterprises that register clinical trials of medicines, which they produce in our country. Currently, they are Farmak, Borschahivsky Chemical Pharmaceutical Plant, Darnitsa pharmaceutical company, Biopharma and Interchem. They are trying to create medicines to treat COVID-19, including symptomatic ones. For example, Darnitsa brought in a substance for the production of hydroxychloroquine, while Biopharma registered a clinical trial of Bioven,” he said during a press briefing in Kyiv on Wednesday, May 13.
Biopharma pharmaceutical company (Kyiv) urges citizens who came through coronavirus (COVID-19) to become plasma donors to develop a medicine against this disease, which the company is launching. The company told Interfax-Ukraine that hyperimmune immunoglobulin may be effective for specific treatment of COVID-19.
The development of the medicine is carried out under Biopharma’s participation in the work of the International alliance of companies specializing in the production of blood plasma medicines, which also includes Takeda and CSL, Octapharma, Biotest, BPL, LFB, Sanquin, GreenCros, ADMA Biologics.
“Our plasma centers in Sumy, Cherkasy, Dnipro, Kharkiv began plasma blank. All the facilities of our plant in Bila Tserkva, all the forces of our team are directed to the development of medicines. I am sure that effective treatment of COVID-19 will appear,” co-owner of the company Kostiantyn Yefymenko wrote on Facebook.
In turn, businessman Vasyl Khmelnytsky, a co-owner of Biopharma as well, said that the development of an effective medicine against COVID-19 requires the support of people around the world who are ready to donate their plasma after coming through the disease.
“We urge those who have recovered to contribute to the fight against the pandemic and, if their health allows, to become a donor,” he wrote on Facebook.
The company said that Biopharma urged all survivors who wish to become blood plasma donors to contact the company’s hotline. Donors will be transported to their plasma centers, where blood plasma can be donated, and back, and they will get compensation for donation.
The company said that it is ready to register and transfer donors from any settlements.
In addition, Biopharma said that one more direction of the fight against coronavirus infection is the clinical study that have begun to evaluate the effectiveness of Bioven medicine manufactured by Biopharma Plazma LLC in the complex treatment of patients with pneumonia caused by COVID-19 and SARS- CoV-2 coronavirus infection.
At least 46 laboratories, including private ones, are diagnosing COVID-19, the Public Health Center said on Facebook on Tuesday.
According to the report, as of April 28, some 98,719 samples were examined by PCR (polymerase chain reaction) in Ukraine.
The Public Health Center notes that persons with suspected coronavirus who had contact with a patient with confirmed COVID-19, patients with pneumonia, health workers (every five days) and patients who recovered (to withdraw a diagnosis) should be tested.